Top three insights from Certainty Europe
The first European Certainty Conference for the Certara Client Community in Mainz Germany was full…
CertaraNovember 21, 2024
Efficient Phase 1 Selection of CAR-T and Lymphodepletion Regimens Using Augmented Definitive Screening Design
How an augmented definitive screening design identified CAR-T and lymphodepletion regimens with 2.37-fold higher odds…
CertaraNovember 20, 2024
Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women
The article "Recent Applications of Pharmacometrics and Systems Pharmacology Approaches to Improve and Optimize Drug…
CertaraNovember 18, 2024
PBPK modeling to support bioequivalence & generic product approvals
Physiologically-based pharmacokinetic modeling can be used to support bioequivalence (BE) assessment of complex and locally…
CertaraNovember 12, 2024
Informing pregnancy dose via target-mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody
The article titled "Informing pregnancy dose via target-mediated drug disposition modeling and simulations for a…
CertaraNovember 4, 2024
Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women
The article titled "Using PBPK modeling to supplement clinical data and support the safe and…
CertaraOctober 30, 2024
Impact of Milk pH and Fat Content on the Prediction of Milk-to-Plasma Ratio
Explore how milk pH and fat content influence drug milk-to-plasma ratio predictions and inform lactation…
CertaraOctober 25, 2024
